ARCHIVES

EGFR Inhibitor Shrinks Tumors In Phase I Study of Patients With Treatment-Resistant Mutation

This article is from The Cancer Letter archive.

Vol. 37 No. 5 | May 30, 2014

Download PDF Visit The Full Archive

Related Articles

NCI Reportedly Gets $691 Million From House, Senate Conferees

October 4, 1974

Colorado Center Delays New Core Grant Application

July 13, 1979

Avon, four companies Fund NABCO Patient Information Services

January 28, 1994

Ibrutinib Demonstrates Responses In Large B-Cell Lymphomas

April 27, 2012

ODAC Recommends Ethyol, DaunoXome For FDA Approval

June 16, 1995

NCI relaxes Core Grants Support For Clinical Trials Research

December 11, 1992